3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
avelumab
7
Nivolumab
5
pembrolizumab
4
Specimen Handling
3
Ipilimumab
3
Biopsy
3
cemiplimab
2
atezolizumab
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
tocilizumab
1
talimogene laherparepvec
1
prednylidene
1
poly ICLC
1
lutetium Lu 177 dotatate
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
flt3 ligand protein
1
durvalumab
1
deltacortene
1
Tacrolimus
1
Saline Solution
1
Radiosurgery
1
Radiation
1
Prednisone
1
MAPRE1 protein, human
1
Lutetium-177
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled